Chromos Molecular Systems Inc. ("Chromos"; TSX: CHR), announced today that it has expanded the scope of its collaboration agreement with Pfizer. Under the expanded agreement, Chromos will use its ACE System to develop a cell line for a Pfizer therapeutic protein product candidate. The parties will also initiate a collaborative program to genetically engineer production cell lines.

Canada NewsWire (http://www.newswire.ca/en/releases/archive/January2006/09/c0517.html)